AORT Overview

Artivion, Inc. is engaged in manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The Company operates through two segments, which include Medical Devices and Preservation Services. The medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease, including heart valve disease, aortic aneurysms, and dissections, and, to a lesser extent, other conditions in cardiac and vascular surgery. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products.

Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is51.71 USD with a low forecast of 40.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Artivion Inc revenue for the last quarter amounts to 115.99M USD, increased 19.20

Artivion Inc. EPS for the last quarter amounts to 0.05 USD, decreased -112.82

Artivion Inc (AORT) has 1800 emplpoyees as of April 17 2026.

Today AORT has the market capitalization of 1.78B USD.